Developer docs
API playgroundTry for free, no card

Search company profiles

Mercator MedSystems

Full company profile

uuid0002kf2

Namestring
Mercator MedSystems
Legal namestring
Mercator MedSystems, Inc.
Websiteurl
mercatormed.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Mercator MedSystems’ mission is to become a global leader in interventional, site-specific delivery of therapeutics that improve patient outcomes in vascular disease, oncology, and regenerative medicine. The 15th and 16th Centuries marked the beginning of the Age of Exploration, a time of bold action, vast territorial expansion and profound intellectual discovery. Gerardus Mercator (1512-1594), a mathematician and cartographer, played a key role in these ventures. He was as important to navigation as Copernicus was to astronomy. He perfected a map projection that was the first to represent the spherical surface of the earth in two dimensions. The Mercator Projection effectively transformed navigation, making it possible for ships to deliver cargo safely to any port on the globe. Inspired by the spirit of our namesake, Mercator MedSystems has developed a medical technology that enables the safe and accurate delivery of therapies anywhere in the body, ranging from drugs for diseased blood vessels, to stem cells that regenerate ailing tissues and organs. We believe this breakthrough will allow the expansion of medical therapy and stimulate profound intellectual exploration into new treatments for disease. We invite you to explore our web site, our technology and products, and to follow our progress to a new world of therapeutic delivery.

Short descriptiontext

Mercator MedSystems develops site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Leandro, United States
HQ citystring
San Leandro
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
catheter-based drug delivery, micro-infusion devices, vascular intervention technology, perivascular drug delivery, interventional medical catheters
Industry2 codes
PRIMARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAF
Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Vascular Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Mercator generates revenue from the sale of its proprietary FDA-cleared and CE-marked catheter-based micro-infusion devices, including the Bullfrog Micro-Infusion Device, Leapfrog Micro-Infusion Device, and Blowfish Transbronchial Micro-Infusion Catheter. Products are sold to hospitals and interventional proceduralists for use in angiographic lab settings.

mercatormed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mercator MedSystems develops and commercializes FDA-cleared and CE-marked catheter-based micro-infusion devices that enable site-specific delivery of drugs and biologics into perivascular tissues and airway walls. Its core products — the Bullfrog, Leapfrog, and Blowfish devices — use a balloon-hydraulically-deployed micro-needle to deposit therapeutics around diseased vessels or airways, avoiding the off-target effects of systemic delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 51.3% relative reduction in clinically relevant target lesion failure (6-month) with temsirolimus local delivery in TANGO Phase 2 trial versus sham control
+6 more records
Product overview1 text field

Mercator MedSystems offers a platform of catheter-based micro-infusion technologies for localized drug delivery. The core products include the Bullfrog Micro-Infusion Device and Leapfrog Micro-Infusion Device (for peripheral vasculature), and the Blowfish Transbronchial Micro-Infusion Catheter (for airways). These FDA-cleared and CE-marked devices use a balloon that hydraulically deploys a micro-needle through vessel walls to deposit therapeutics into perivascular tissues, enabling targeted delivery of pharmacologics and biologics instead of systemic administration.

Product and service3 records
1Bullfrog Micro-Infusion Device
CategoryCatheter-Based Micro-Infusion Device
Description

FDA-cleared and CE-marked catheter-based device that uses a balloon-hydraulically-deployed micro-needle to deliver drugs and biologics into perivascular tissues around arteries or veins (2-16 mm diameter). Used by interventional cardiologists, vascular surgeons, and interventional radiologists in angiographic lab settings.

2Leapfrog Micro-Infusion Device
CategoryCatheter-Based Micro-Infusion Device
Description

FDA-cleared and CE-marked catheter-based micro-infusion device similar to the Bullfrog, with a balloon that hydraulically deploys a micro-needle through the vessel wall for perivascular drug delivery.

3Blowfish Transbronchial Micro-Infusion Catheter
CategoryTransbronchial Micro-Infusion Catheter
Description

FDA-cleared and CE-marked catheter for the delivery of drugs and biologics into airways, enabling precision drug delivery to airway walls for treatment of bronchial conditions including malignant airway obstruction, asthma, and chronic bronchitis.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Vascular Breakthroughs, LLC
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-03-07
Description

Vascular Breakthroughs, LLC announced first New England enrollment into the DEXTERITY clinical trials, partnering with Vascular Care Connecticut to expand Mercator's clinical trial site network for local anti-inflammatory DVT therapy studies.

mercatormed.com
2Vascular Care Connecticut
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-03-07
Description

Vascular Care Connecticut partnered with Vascular Breakthroughs, LLC to serve as a clinical trial enrollment site for Mercator's DEXTERITY clinical trials, marking first New England enrollment in the DVT local anti-inflammatory therapy studies.

mercatormed.com
3Massachusetts General Hospital (MGH), Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

MGH research team led by Dr. Farouc Jaffer serves as co-principal investigator for the NIH STTR grant research. The collaboration focuses on preclinical models to demonstrate mechanisms of DVT and restoration of blood flow, measuring molecular, physiologic, and biologic outcomes of anti-inflammatory drug delivery locally around veins. The partnership leverages MGH's extensive experience in preclinical DVT modeling.

mercatormed.com
4Sentara Healthcare / Sentara Norfolk General Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-29
Description

Dr. David Dexter of Sentara Vascular Specialists enrolled the first patient in the DEXTERITY-AFP clinical trial on October 29, 2021, at Sentara Norfolk General Hospital in Virginia. Dr. Dexter serves as Principal Investigator and worldwide co-Principal Investigator for the DEXTERITY-AFP trial, playing a central role in Mercator's key clinical development program for DVT treatment.

mercatormed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Penumbra
TypeDirect peer
Description

Penumbra's Indigo System is a leading catheter-based thrombectomy device for DVT treatment, directly competing with Mercator's DEXTERITY program in the same physician call point (interventional radiologists/vascular surgeons) and addressing the same post-thrombotic syndrome population.

2AngioDynamics
TypeDirect peer
Description

AngioDynamics manufactures vascular interventional devices including mechanical thrombectomy (AlphaVac, AngioJet) and ablation catheters, serving the same endovascular specialists who would adopt Mercator's micro-infusion devices for DVT and below-knee PAD.

3SurModics
TypeEmerging player
Description

SurModics develops drug-delivery coating technologies for vascular devices, addressing the same clinical need (restenosis prevention) through surface drug elution rather than Mercator's perivascular micro-infusion, making it the most direct technology analogue in the local-delivery space.

4BioCardia
5Cardiovascular Systems (Abbott)
TypeBroad incumbent
Description

CSI (acquired by Abbott) developed Diamondback atherectomy for peripheral arterial disease including below-knee lesions, directly competing for the same procedural slot in below-knee revascularization where Mercator's TANGO trial temsirolimus delivery is positioned.

6Shockwave Medical (Johnson & Johnson)
TypeBroad incumbent
Description

Shockwave's intravascular lithotripsy (IVL) for calcified peripheral and coronary artery disease targets the same vascular interventional call points and increasingly competes with drug-based approaches for below-knee PAD treatment.

7Medtronic
TypeBroad incumbent
Description

Medtronic is a dominant interventional cardiology and peripheral vascular device manufacturer with drug-coated balloons (IN.PACT) and renal denervation programs that compete with Mercator's perivascular micro-infusion across DVT, PAD, and hypertension indications.

8Boston Scientific
TypeBroad incumbent
Description

Boston Scientific's peripheral interventional portfolio (Eluvia drug-eluting stent, Ranger DCB) and interventional oncology/catheter platforms overlap with Mercator's addressable indications and physician customer base.

9Abbott Vascular
TypeBroad incumbent
Description

Abbott's vascular division (XIENCE, Esprit, StarClose) competes in peripheral and coronary vascular intervention with both drug-eluting and mechanical solutions that target overlapping patient populations with Mercator's micro-infusion devices.

10RenovaCare
TypeEmerging player
Description

RenovaCare develops cell spray and local delivery technologies for regenerative medicine and wound care, sharing Mercator's platform-based approach to localized therapeutic delivery outside of systemic administration.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mercator MedSystems

Interventional Vascular Medical Devicesmercatormed.com

Mercator MedSystems develops site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.

What Mercator MedSystems does

Mercator MedSystems’ mission is to become a global leader in interventional, site-specific delivery of therapeutics that improve patient outcomes in vascular disease, oncology, and regenerative medicine. The 15th and 16th Centuries marked the beginning of the Age of Exploration, a time of bold action, vast territorial expansion and profound intellectual discovery. Gerardus Mercator (1512-1594), a mathematician and cartographer, played a key role in these ventures. He was as important to navigation as Copernicus was to astronomy. He perfected a map projection that was the first to represent the spherical surface of the earth in two dimensions. The Mercator Projection effectively transformed navigation, making it possible for ships to deliver cargo safely to any port on the globe. Inspired by the spirit of our namesake, Mercator MedSystems has developed a medical technology that enables the safe and accurate delivery of therapies anywhere in the body, ranging from drugs for diseased blood vessels, to stem cells that regenerate ailing tissues and organs. We believe this breakthrough will allow the expansion of medical therapy and stimulate profound intellectual exploration into new treatments for disease. We invite you to explore our web site, our technology and products, and to follow our progress to a new world of therapeutic delivery.

Mercator MedSystems firmographics

Firmographics
Name
Mercator MedSystems
Legal name
Mercator MedSystems, Inc.
Website
https://mercatormed.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Mercator MedSystems develops site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.
Ownership category
akta.pro rank

Mercator MedSystems industry classification

Industry
Product category
Interventional Vascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAF
Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Catheter-based drug delivery
  • Micro-infusion devices
  • Vascular intervention technology
  • Perivascular drug delivery
  • Interventional medical catheters

Where Mercator MedSystems is headquartered

Location

Headquarters

HQ city
San Leandro
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Mercator MedSystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: Mercator generates revenue from the sale of its proprietary FDA-cleared and CE-marked catheter-based micro-infusion devices, including the Bullfrog Micro-Infusion Device, Leapfrog Micro-Infusion Device, and Blowfish Transbronchial Micro-Infusion Catheter. Products are sold to hospitals and interventional proceduralists for use in angiographic lab settings.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Mercator MedSystems product offering

Product offering

Core offering

Mercator MedSystems develops and commercializes FDA-cleared and CE-marked catheter-based micro-infusion devices that enable site-specific delivery of drugs and biologics into perivascular tissues and airway walls. Its core products — the Bullfrog, Leapfrog, and Blowfish devices — use a balloon-hydraulically-deployed micro-needle to deposit therapeutics around diseased vessels or airways, avoiding the off-target effects of systemic delivery.

Product overview

Mercator MedSystems offers a platform of catheter-based micro-infusion technologies for localized drug delivery. The core products include the Bullfrog Micro-Infusion Device and Leapfrog Micro-Infusion Device (for peripheral vasculature), and the Blowfish Transbronchial Micro-Infusion Catheter (for airways). These FDA-cleared and CE-marked devices use a balloon that hydraulically deploys a micro-needle through vessel walls to deposit therapeutics into perivascular tissues, enabling targeted delivery of pharmacologics and biologics instead of systemic administration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bullfrog Micro-Infusion Device FDA-cleared and CE-marked catheter-based device that uses a balloon-hydraulically-deployed micro-needle to deliver drugs and biologics into perivascular tissues around arteries or veins (2-16 mm diameter). Used by interventional cardiologists, vascular surgeons, and interventional radiologists in angiographic lab settings.
  • Leapfrog Micro-Infusion Device FDA-cleared and CE-marked catheter-based micro-infusion device similar to the Bullfrog, with a balloon that hydraulically deploys a micro-needle through the vessel wall for perivascular drug delivery.
  • Blowfish Transbronchial Micro-Infusion Catheter FDA-cleared and CE-marked catheter for the delivery of drugs and biologics into airways, enabling precision drug delivery to airway walls for treatment of bronchial conditions including malignant airway obstruction, asthma, and chronic bronchitis.

Quantifiable outcome

  • 51.3% relative reduction in clinically relevant target lesion failure (6-month) with temsirolimus local delivery in TANGO Phase 2 trial versus sham control
  • +6 more outcomes

Companies that use Mercator MedSystems

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Mercator MedSystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mercator MedSystems partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Vascular Breakthroughs, LLCminorStrategic or Co-development Partner · 7 March 2022Vascular Breakthroughs, LLC announced first New England enrollment into the DEXTERITY clinical trials, partnering with Vascular Care Connecticut to expand Mercator's clinical trial site network for local anti-inflammatory DVT therapy studies.
  • Vascular Care ConnecticutminorStrategic or Co-development Partner · 7 March 2022Vascular Care Connecticut partnered with Vascular Breakthroughs, LLC to serve as a clinical trial enrollment site for Mercator's DEXTERITY clinical trials, marking first New England enrollment in the DVT local anti-inflammatory therapy studies.
  • Massachusetts General Hospital (MGH), Harvard Medical SchoolcoreStrategic or Co-development Partner · 1 January 2022MGH research team led by Dr. Farouc Jaffer serves as co-principal investigator for the NIH STTR grant research. The collaboration focuses on preclinical models to demonstrate mechanisms of DVT and restoration of blood flow, measuring molecular, physiologic, and biologic outcomes of anti-inflammatory drug delivery locally around veins. The partnership leverages MGH's extensive experience in preclinical DVT modeling.
  • Sentara Healthcare / Sentara Norfolk General HospitalcoreStrategic or Co-development Partner · 29 October 2021Dr. David Dexter of Sentara Vascular Specialists enrolled the first patient in the DEXTERITY-AFP clinical trial on October 29, 2021, at Sentara Norfolk General Hospital in Virginia. Dr. Dexter serves as Principal Investigator and worldwide co-Principal Investigator for the DEXTERITY-AFP trial, playing a central role in Mercator's key clinical development program for DVT treatment.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Mercator MedSystems competitors and assessment

Company assessment

Direct peers

  • Penumbra: Penumbra's Indigo System is a leading catheter-based thrombectomy device for DVT treatment, directly competing with Mercator's DEXTERITY program in the same physician call point (interventional radiologists/vascular surgeons) and addressing the same post-thrombotic syndrome population.
  • AngioDynamics: AngioDynamics manufactures vascular interventional devices including mechanical thrombectomy (AlphaVac, AngioJet) and ablation catheters, serving the same endovascular specialists who would adopt Mercator's micro-infusion devices for DVT and below-knee PAD.

Emerging players

  • SurModics: SurModics develops drug-delivery coating technologies for vascular devices, addressing the same clinical need (restenosis prevention) through surface drug elution rather than Mercator's perivascular micro-infusion, making it the most direct technology analogue in the local-delivery space.
  • RenovaCare: RenovaCare develops cell spray and local delivery technologies for regenerative medicine and wound care, sharing Mercator's platform-based approach to localized therapeutic delivery outside of systemic administration.

Peers

  • BioCardia:

Broad incumbents

  • Cardiovascular Systems (Abbott): CSI (acquired by Abbott) developed Diamondback atherectomy for peripheral arterial disease including below-knee lesions, directly competing for the same procedural slot in below-knee revascularization where Mercator's TANGO trial temsirolimus delivery is positioned.
  • Shockwave Medical (Johnson & Johnson): Shockwave's intravascular lithotripsy (IVL) for calcified peripheral and coronary artery disease targets the same vascular interventional call points and increasingly competes with drug-based approaches for below-knee PAD treatment.
  • Medtronic: Medtronic is a dominant interventional cardiology and peripheral vascular device manufacturer with drug-coated balloons (IN.PACT) and renal denervation programs that compete with Mercator's perivascular micro-infusion across DVT, PAD, and hypertension indications.
  • Boston Scientific: Boston Scientific's peripheral interventional portfolio (Eluvia drug-eluting stent, Ranger DCB) and interventional oncology/catheter platforms overlap with Mercator's addressable indications and physician customer base.
  • Abbott Vascular: Abbott's vascular division (XIENCE, Esprit, StarClose) competes in peripheral and coronary vascular intervention with both drug-eluting and mechanical solutions that target overlapping patient populations with Mercator's micro-infusion devices.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mercator MedSystems social profiles

Digital presence

Mercator MedSystems compliance and trust

Trust signal

Compliance2 records

Mercator MedSystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mercator MedSystems leadership team

Management profile

Number of profiles

Profiles8 records

Mercator MedSystems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mercator MedSystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mercator MedSystems

What does Mercator MedSystems do?

Mercator MedSystems develops and commercializes FDA-cleared and CE-marked catheter-based micro-infusion devices that enable site-specific delivery of drugs and biologics into perivascular tissues and airway walls. Its core products — the Bullfrog, Leapfrog, and Blowfish devices — use a balloon-hydraulically-deployed micro-needle to deposit therapeutics around diseased vessels or airways, avoiding the off-target effects of systemic delivery.

Is Mercator MedSystems a public or private company?

Mercator MedSystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mercator MedSystems founded?

Mercator MedSystems was founded in 2000. It employs 11 to 50 people.

Where is Mercator MedSystems based?

Mercator MedSystems is headquartered in San Leandro, United States, in the North America region.

How does Mercator MedSystems make money?

One revenue line is on record: medical Device Sales.

Who are Mercator MedSystems's main competitors?

Direct peers on record are Penumbra and AngioDynamics. Emerging players are SurModics and RenovaCare. BioCardia is listed as a peer. Broad incumbents are Cardiovascular Systems (Abbott), Shockwave Medical (Johnson & Johnson), Medtronic, Boston Scientific and Abbott Vascular.

Does Mercator MedSystems have an API?

No public API is recorded for Mercator MedSystems.

What industry is Mercator MedSystems in?

Mercator MedSystems's product category is Interventional Vascular Medical Devices. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAHAGAF, Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VenousnewsFirst New England enrolment into the DEXTERITY clinical trials announcedVascular Breakthroughs and Vascular Care Connecticut have enrolled their first patient in the DEXTERITY clinical trials, sponsored by Mercator MedSystems. These trials evaluate an anti-inflammatory steroid therapy delivered via a cardiovascular catheter to improve outcomes for deep vein thrombosis patients. The enrolment marks a key milestone in testing this novel treatment for both recent and long-standing symptoms.Business Wire BlogVascular Breakthroughs, LLC, and Vascular Care Connecticut Announce First New England Enrollment into the Novel DEXTERITY Clinical Trials of Local Anti-Inflammatory Therapy to Improve Outcomes of DeepVascular Breakthroughs, LLC and Vascular Care Connecticut enrolled their first patient in the DEXTERITY clinical trials for deep vein thrombosis therapy. The trials are sponsored by Mercator MedSystems, Inc., which is testing a local anti-inflammatory steroid delivery system to improve patient outcomes.VenousnewsFirst patient enrolled in DEXTERITY-AFP clinical trialMercator MedSystems announced the enrollment of the first patient in its DEXTERITY-AFP Phase 2 clinical trial, which evaluates a local anti-inflammatory therapy for deep vein thrombosis (DVT). The study utilizes Mercator’s proprietary Bullfrog micro-infusion device to deliver dexamethasone directly to affected veins, aiming to reduce inflammation following thrombus removal. This marks the initiation of the first locally targeted drug therapy designed specifically to address DVT-related inflammation.PR NewswireMercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX TrialMercator MedSystems announced completion of enrollment in the LIMBO-ATX clinical trial, a prospective, multi-center, randomized, controlled study testing the company's Bullfrog micro-infusion catheter to deliver dexamethasone for treating below-the-knee critical limb ischemia. The trial enrolled over 100 patients with arterial obstructions and will measure outcomes including improvement in blood flow and reduction of repeat revascularization procedures, with primary 6-month endpoint data expected in Q2 2018.VascularnewsFirst patients enrolled in Mercator MedSystems TANGO trialMercator MedSystems has enrolled the first patient in its TANGO clinical trial, which evaluates the use of the company's Bullfrog micro-infusion device for delivering temsirolimus to below-the-knee lesions. The study aims to treat critical limb ischaemia by providing local drug delivery without permanent implants, recruiting approximately 60 patients across multiple centers. Temsirolimus is a drug manufactured by Pfizer.PR NewswireMercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular DiseaseMercator MedSystems announced the first patient enrollment in the TANGO clinical trial, a Phase 2 study evaluating the company's Bullfrog Micro-Infusion Device for delivering Pfizer's TORISEL (temsirolimus) to treat critical limb ischemia in below-the-knee arteries after revascularization. The trial is a prospective, multi-center, randomized, dose-escalation study recruiting approximately 60 patients at up to 15 centers in the U.S., representing the first U.S. clinical trial of local -limus agent delivery without a permanent implant for lesions longer than 5 centimeters. The study is funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH.PR NewswireClinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINCMercator MedSystems announced 13-month data from its DANCE clinical trial at ISET in Hollywood, Florida and LINC in Leipzig, Germany, using the Bullfrog Micro-Infusion Device to deliver dexamethasone to tissues around femoropopliteal arteries after revascularization. The trial enrolled 281 limbs across two groups and reported primary patency rates of 80-83.6% at 13 months with no device or drug-related adverse events. CEO Trent Reutiman stated that the results validate the Bullfrog device's capability for targeted micro-infusion drug delivery, representing a potential approach alternative to drug-coated balloons or drug-eluting stents.PR NewswireFierce Innovation Awards: Life Sciences Edition Announce Finalists, Mercator MedSystems RecognizedMercator MedSystems was named a finalist in the Fierce Innovation Awards: Life Sciences Edition in the Drug Delivery Technology category for its Bullfrog Micro-Infusion Device. The Bullfrog Device is an FDA 510(k)-cleared and CE-Marked system designed to infuse therapeutic agents directly through blood vessel walls into adventitial and perivascular tissues, currently being evaluated for locally delivering dexamethasone to prevent restenosis in peripheral artery disease patients. Winners of the competition will be announced on December 21, 2016.PR NewswireFinal Six Late-Breaking Endovascular Clinical Trial Results Announced at VIVA 16VIVA Physicians announced late-breaking clinical trial results at the VIVA 16 conference in Las Vegas, presenting data on six endovascular devices and procedures. The trials demonstrated the safety and efficacy of specific products from Abbott Vascular, Bard Peripheral Vascular, Mercator MedSystems, and Penumbra, Inc., including bioresorbable scaffolds, covered stents, and aspiration systems. Key findings included high patency rates for various stents and confirmation that carotid stent fractures were not associated with major adverse clinical events.DAICFirst Patients Enrolled in Mercator MedSystems’ U.S. Below the Knee Clinical TrialMercator MedSystems announced the enrollment of the first patients in its LIMBO-ATX clinical trial for critical limb ischemia, which was approved by the U.S. FDA. The study utilizes the company's proprietary Bullfrog Micro-Infusion Device to deliver anti-inflammatory steroids during atherectomy procedures to prevent arterial re-occlusion. Up to 120 patients are planned for enrollment across sites including the University of North Carolina and Guadalupe Regional Hospital.